| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,560,000 |
| Market
Cap: |
203.82(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.89 - $14.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.3 |
| Insider 3/6 Months : 21.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Solid Biosciences is engaged in curing Duchenne muscular dystrophy (Duchenne), a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are Co.'s gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Co.'s SGT-001 and SGT-003 vectors are derived from a naturally occurring, non-pathogenic virus called adeno-associated virus, which were selected for their ability to enter skeletal, diaphragm and cardiac muscle tissues.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
4,314,873 |
4,314,873 |
4,314,873 |
| Total Buy Value |
$0 |
$23,861,248 |
$23,861,248 |
$23,861,248 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
462 |
35,539 |
35,539 |
37,990 |
| Total Sell Value |
$4,772 |
$126,957 |
$126,957 |
$144,031 |
| Total People Sold |
1 |
7 |
7 |
8 |
| Total Sell Transactions |
1 |
9 |
9 |
13 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ganot Ilan |
CEO & President |
• • – |
2019-07-25 |
4 |
A |
$4.65 |
$99,998 |
D/D |
21,505 |
1,123,631 |
|
- |
|
| Freed Martin I |
Director |
– • – |
2019-07-25 |
4 |
A |
$4.65 |
$249,998 |
D/D |
53,763 |
53,763 |
|
- |
|
| Nagendran Sukumar |
Director |
– • – |
2019-07-25 |
4 |
A |
$4.65 |
$150,000 |
D/D |
32,258 |
34,258 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2019-07-25 |
4 |
B |
$4.65 |
$13,125,002 |
I/I |
2,822,581 |
6,749,803 |
1.5 |
- |
|
| Shah Rajeev M. |
Director |
– • – |
2019-07-25 |
4 |
A |
$4.65 |
$8,749,998 |
I/I |
1,881,720 |
4,571,164 |
|
- |
|
| Arnold Matthew Bennett |
Director |
– • – |
2019-07-25 |
4 |
A |
$4.65 |
$3,149,998 |
D/D |
677,419 |
3,500,997 |
|
- |
|
| Morris Carl Ashley |
Chief Scientific Officer |
• – – |
2019-07-25 |
4 |
A |
$4.65 |
$99,998 |
D/D |
21,505 |
133,050 |
|
- |
|
| Arnold Matthew Bennett |
Director |
– • – |
2019-06-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
562,715 |
2,823,578 |
|
- |
|
| Zarur Juan Andrey |
Director |
– • – |
2019-05-08 |
4 |
AS |
$10.00 |
$80,039 |
I/I |
(8,000) |
10,189 |
|
- |
|
| Boxer Capital, Llc |
10% Owner |
– – • |
2019-03-28 |
4 |
S |
$9.53 |
$571,800 |
D/D |
(60,000) |
3,473,272 |
|
- |
|
| Boxer Capital, Llc |
10% Owner |
– – • |
2019-03-27 |
4 |
S |
$9.60 |
$1,104,000 |
D/D |
(115,000) |
3,533,272 |
|
- |
|
| Boxer Capital, Llc |
10% Owner |
– – • |
2019-03-26 |
4 |
S |
$10.08 |
$2,772,000 |
D/D |
(275,000) |
3,648,272 |
|
- |
|
| Mva Investors, Llc |
10% Owner |
– – • |
2019-03-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,964,970 |
|
- |
|
| Arnold Matthew Bennett |
Director |
– • – |
2019-01-14 |
4 |
AS |
$31.60 |
$159,982 |
D/D |
(5,000) |
3,386,293 |
|
- |
|
| Arnold Matthew Bennett |
Director |
– • – |
2019-01-07 |
4 |
AS |
$30.08 |
$150,407 |
D/D |
(5,000) |
3,391,293 |
|
- |
|
| Amorrortu Pedro Alvaro |
Chief Operating Officer |
• – – |
2019-01-04 |
4/A |
AS |
$30.07 |
$270,619 |
D/D |
(9,000) |
153,746 |
|
- |
|
| Amorrortu Pedro Alvaro |
Chief Operating Officer |
• – – |
2019-01-04 |
4 |
AS |
$30.07 |
$270,619 |
D/D |
(9,000) |
158,046 |
|
- |
|
| Amorrortu Pedro Alvaro |
Chief Operating Officer |
• – – |
2018-12-03 |
4/A |
AS |
$30.20 |
$279,534 |
D/D |
(9,000) |
162,746 |
|
- |
|
| Amorrortu Pedro Alvaro |
Chief Operating Officer |
• – – |
2018-12-03 |
4 |
AS |
$30.20 |
$279,534 |
D/D |
(9,000) |
167,046 |
|
- |
|
| Quiroz Jorge Armando |
Chief Medical Officer |
• – – |
2018-12-03 |
4 |
AS |
$29.94 |
$1,253,145 |
D/D |
(40,150) |
228,092 |
|
- |
|
| Quiroz Jorge Armando |
Chief Medical Officer |
• – – |
2018-11-16 |
4 |
AS |
$34.90 |
$3,490 |
D/D |
(100) |
268,242 |
|
- |
|
| Zarur Juan Andrey |
Director |
– • – |
2018-11-16 |
4 |
AS |
$35.00 |
$3,500 |
D/D |
(100) |
691,105 |
|
- |
|
| Schneider Joel Solomon Zev |
See Remarks |
• – – |
2018-11-15 |
4/A |
AS |
$30.68 |
$678,180 |
D/D |
(21,990) |
124,656 |
|
- |
|
| Ganot Ilan |
CEO & President |
• • – |
2018-11-15 |
4 |
AS |
$30.70 |
$1,541,933 |
D/D |
(50,000) |
1,102,126 |
|
- |
|
| Amorrortu Pedro Alvaro |
Chief Operating Officer |
• – – |
2018-11-15 |
4 |
AS |
$30.61 |
$277,478 |
D/D |
(9,000) |
171,746 |
|
- |
|
131 Records found
|
|
Page 5 of 6 |
|
|
0.42 (4.2%) 
